InDream Healthcare Launches 'MyChart' Polypharmacy App

Indream Healthcare is introducing an innovative solution for complex polypharmacy management, bringing a new wave to the digital healthcare market. The recently officially launched patient app, 'Indream MyChart', is a smart service that automatically collects and organizes medication information simply through mobile phone identity verification. It is particularly noteworthy for providing strict safety data from overseas, going beyond the standards of Korea's Drug Utilization Review (DUR) service. 'MyChart' has been meticulously designed to help patients easily identify their medication risks, including severe drug interactions, medication safety ratings during pregnancy and lactation, medications to be cautious with for the elderly, common side effects, and QT prolongation risk. The true value of this app shines through its organic linkage with 'Indream MediSupport', a solution for medical professionals. Risk signals detected in MyChart are transmitted to medical professionals in real-time for review, functioning as a powerful tool that deeply analyzes the patient's polypharmacy status and supports medical professionals in making accurate prescribing decisions. Currently, 'Indream MediSupport' is successfully operating at Jeju National University Hospital, and its adoption at Ilsan CHA Hospital has also been confirmed, expanding its scope of utilization in clinical settings. CEO Kang Byung-joo defined this 'MyChart-MediSupport integrated ecosystem' as a "precision medicine tool for managing complex polypharmacy prescriptions," emphasizing that it will contribute to solving national drug safety issues in conjunction with the government's polypharmacy management policies. This integrated system is setting new standards for medication management through a variety of functions, including real-time detection of drug interactions and risks, actionable alerts for medical professionals, streamlined clinical workflows, data integration between heterogeneous systems, and personalized prescription support. Indream Healthcare, infused with the expertise of CEO Kang Byung-joo, who graduated from Yonsei University College of Medicine and served as a specialist at Asan Medical Center and an associate professor at Jeju National University College of Medicine, has already been recognized for its innovativeness, including receiving ministerial awards from the Ministry of Health and Welfare and the Ministry of Science and ICT in 2022, and recognition at the 2025 Lina50+ Awards. As a social venture pursuing social value, it is dedicated to research and development, occupying spaces in prominent institutions such as the Open Lab at Korea University Guro Hospital. Based on active collaborations with domestic and international hospitals and research institutions, Indream Healthcare is also actively pursuing entry into the global market, further raising expectations for the future of drug safety management it will present.